Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors

International Journal of Cancer

Volumn 132, Issue 10, 2013, Pages 2339-2348

  Chandramohan, Vidyalakshmi ^a   Bao, Xuhui ^a,b   Kato Kaneko, Mika ^c   Kato, Yukinari ^c   Keir, Stephen T ^a   Szafranski, Scott E ^a   Kuan, Chien Tsun ^a   Pastan, Ira H ^d   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

^c YAMAGATA UNIVERSITY   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

glioblastoma multiforme; medulloblastoma; podoplanin; recombinant immunotoxin; single chain disulfide Fv

Indexed keywords

IMMUNOTOXIN; NZ 1 (SINGLE CHAIN DISULFIDE FV)LYSYLASPARTYLGLUTAMLYLEUCINE; PODOPLANIN; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DISULFIDE BOND; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTERNALIZATION; MALE; MEDULLOBLASTOMA; MOLECULAR CLONING; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN STABILITY; TUMOR CELL; TUMOR REGRESSION; TUMOR XENOGRAFT;

ADP RIBOSE TRANSFERASES; BACTERIAL TOXINS; BRAIN NEOPLASMS; CELL LINE, TUMOR; EXOTOXINS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRULENCE FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874941321     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27919     Document Type: Article

References (32)

1. http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf.
2. Scott JN, Rewcastle NB, Brasher PM, et al. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol 1999; 46: 183-8.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
4. Vredenburgh JJ, Desjardins A, Herndon JE II, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-9.
5. Giangaspero F, Eberhardt CG, Haapasalo H, et al. Medulloblastoma. In:, Louis DN, Ohgaki H, Wiestler OD, et al., eds. WHO classification of tumours of the central nervous system, 4th edn. Lyon, France: International Agency for Research on Cancer, 2007. 132-40.
6. Roussel MF, Robinson G,. Medulloblastoma: advances and challenges. F1000 Biol Rep 2011; 3: 5.
7. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-710.
8. Thaker NG, Pollack IF,. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother 2009; 9: 1815-36.
9. Bullard DE, Bigner DD,. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors. J Neurosurg 1985; 63: 2-16.
10. Weldon JE, Pastan I,. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011; 278: 4683-700.
11. Raica M, Cimpean AM, Ribatti D,. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008; 28: 2997-3006.
12. Schacht V, Ramirez MI, Hong YK, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003; 22: 3546-56.
13. Mishima K, Kato Y, Kaneko MK, et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111: 483-8.
14. Shibahara J, Kashima T, Kikuchi Y, et al. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 2006; 448: 493-9.
15. Kato Y, Kaneko MK, Kunita A, et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99: 54-61.
16. Kunita A, Kashima TG, Morishita Y, et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007; 170: 1337-47.
17. Martin-Villar E, Megias D, Castel S, et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006; 119: 4541-53.
18. Wicki A, Lehembre F, Wick N, et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9: 261-72.
19. Ogasawara S, Kaneko MK, Price JE, et al. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt) 2008; 27: 259-67.
20. Kato Y, Kaneko MK, Kuno A, et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006; 349: 1301-7.
21. Kato Y, Vaidyanathan G, Kaneko MK, et al. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol 2010; 37: 785-94.
22. Lambson BE, Bernstein R, Mendelow BV,. Chromosomal evolution in secretory and nonsecretory subline of MOPC 21. Somat Cell Mol Genet 1990; 16: 91-5.
23. Buchner J, Pastan I, Brinkmann U,. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 1992; 205: 263-70.
24. Beers R, Chowdhury P, Bigner D, et al. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. Clin Cancer Res 2000; 6: 2835-43.
25. Friedman HS, Houghton PJ, Schold SC, et al. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1994; 34: 171-4.
26. Friedman HS, Colvin OM, Skapek SX, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 1988; 48: 4189-95.
27. Gehan EA,. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203-23.
28. Reiter Y, Brinkmann U, Lee B, et al. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat Biotechnol 1996; 14: 1239-45.
29. Wikstrand CJ, McLendon RE, Friedman AH, et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997; 57: 4130-40.
30. Li YM, Hall WA,. Targeted toxins in brain tumor therapy. Toxins (Basel) 2010; 2: 2645-62.
31. Sampson JH, Brady M, Raghavan R, et al. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery 2011; 69: 668-76.
32. Reiter Y, Pastan I,. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins. Clin Cancer Res 1996; 2: 245-52.